FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Salah-Eddin Al-Batran, Martin H. Schuler, Zanete Zvirbule, Georgiy Manikhas, Florian Lordick, Andriy Rusyn, Yuriy Vynnyk, Ihor Vynnychenko, Natalia Fadeeva, Marina Nechaeva, Assen Dudov, Evgeny Gotovkin, Alexander Pecheniy, Igor Bazin, Igor Bondarenko, Bohuslav Melichar, Christian Mueller, Christoph Huber, Oezlem Tureci, Ugur Sahin
Institutions: Institute of Clinical Cancer Research, Krankenhaus Nordwest, Deutsches Konsortium für Translationale Krebsforschung, University of Duisburg-Essen, Riga East University Hospital, City Clinical Oncology Center, University Hospital Leipzig, Sumy State University, Chelyabinsk Regional Clinical Oncology Center, Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser, Queen Giovanna Hospital, Russian Cancer Research Center NN Blokhin, Dnipro State Medical University, Palacký University Olomouc, Mainzer Zentrum für Digitalität in den Geistes- und Kulturwissenschaften, University Medical Center of the Johannes Gutenberg University Mainz, Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4235452425